Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012)
CHOP‐based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance‐free CHOP‐based protocols have been published and readily used in dogs, there is limited literature regarding similar maintenance‐...
Gespeichert in:
| Veröffentlicht in: | Veterinary & comparative oncology 2016-08, Vol.14 (S1), p.136-146 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | S1 |
| container_start_page | 136 |
| container_title | Veterinary & comparative oncology |
| container_volume | 14 |
| creator | Collette, S. A. Allstadt, S. D. Chon, E. M. Vernau, W. Smith, A. N. Garrett, L. D. Choy, K. Rebhun, R. B. Rodriguez Jr, C. O. Skorupski, K. A. |
| description | CHOP‐based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance‐free CHOP‐based protocols have been published and readily used in dogs, there is limited literature regarding similar maintenance‐free protocols in cats. The purpose of this study was to describe the outcome of cats with intermediate‐ to high‐grade lymphoma that were prescribed a modified 25‐week University of Wisconsin–Madison (UW‐25) chemotherapy protocol. A secondary objective was examination of potential prognostic factors. One hundred and nineteen cats from five institutions treated with a UW‐25‐based protocol were included. The Kaplan–Meier median progression‐free interval (PFI) and survival time (MST) were 56 and 97 (range 2–2019) days, respectively. Cats assessed as having a complete response (CR) to therapy had significantly longer PFI and MST than those with partial or no response (PFI 205 versus 54 versus 21 days, respectively, P |
| doi_str_mv | 10.1111/vco.12158 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5012421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1846313300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6818-87747d3d4cf4801425adcedfa40f6ee274d15768b753b41fe547ebc61270a4ee3</originalsourceid><addsrcrecordid>eNqNkc1uEzEURkcIREthwQsgL9vFtLbHf2GBVEXQIgW6KbRiYzn2nYxhZhxsJyWPwFvwLDwZLmkjWCDhjS353KP76auq5wQfk3JO1jYcE0q4elDtEyZFzRWdPNy9Cd6rnqT0GWNKWUMfV3tUEDyhku9X3y8jmDzAmFFoUQu9HwH5MUMcwHmToUY5_PzR-UVXL6JxgPrNsOzCYNCNzx0yaAjOtx4cWo1-DTH5vLlVXflkw5j8WL8zzqcwomUMOdjQv0SETJA1CRI6pBizmmJCj55Wj1rTJ3h2dx9UH968vpye17OLs7fT01lthSKqVlIy6RrHbMsUJoxy4yy41jDcCgAqmSNcCjWXvJkz0gJnEuZWECqxYQDNQfVq612u5iWjLdGj6fUy-sHEjQ7G679_Rt_pRVhrXrZklBTB4Z0ghq8rSFkPJSv0vRkhrJImiomGNA3G_4ESrIRkShT0aIvaGFKK0O42IljftqxLy_p3y4V98WeEHXlfawFOtsCN72Hzb5P-OL24V9bbCZ8yfNtNmPhFC9lIrq_en-nz69mn6xmfadH8AgAewdo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1810867486</pqid></control><display><type>article</type><title>Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Collette, S. A. ; Allstadt, S. D. ; Chon, E. M. ; Vernau, W. ; Smith, A. N. ; Garrett, L. D. ; Choy, K. ; Rebhun, R. B. ; Rodriguez Jr, C. O. ; Skorupski, K. A.</creator><creatorcontrib>Collette, S. A. ; Allstadt, S. D. ; Chon, E. M. ; Vernau, W. ; Smith, A. N. ; Garrett, L. D. ; Choy, K. ; Rebhun, R. B. ; Rodriguez Jr, C. O. ; Skorupski, K. A.</creatorcontrib><description>CHOP‐based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance‐free CHOP‐based protocols have been published and readily used in dogs, there is limited literature regarding similar maintenance‐free protocols in cats. The purpose of this study was to describe the outcome of cats with intermediate‐ to high‐grade lymphoma that were prescribed a modified 25‐week University of Wisconsin–Madison (UW‐25) chemotherapy protocol. A secondary objective was examination of potential prognostic factors. One hundred and nineteen cats from five institutions treated with a UW‐25‐based protocol were included. The Kaplan–Meier median progression‐free interval (PFI) and survival time (MST) were 56 and 97 (range 2–2019) days, respectively. Cats assessed as having a complete response (CR) to therapy had significantly longer PFI and MST than those with partial or no response (PFI 205 versus 54 versus 21 days, respectively, P < 0.0001 and MST 318 versus 85 versus 27 days, respectively, P < 0.0001).</description><identifier>ISSN: 1476-5810</identifier><identifier>EISSN: 1476-5829</identifier><identifier>DOI: 10.1111/vco.12158</identifier><identifier>PMID: 26109275</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>alkaloids ; Animals ; Antibiotics, Antineoplastic - pharmacology ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents, Alkylating - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; cat ; Cat Diseases - drug therapy ; Cats ; CHOP ; cyclophosphamide ; Cyclophosphamide - pharmacology ; dogs ; doxorubicin ; Doxorubicin - pharmacology ; drug therapy ; feline ; Female ; Kaplan-Meier Estimate ; lymphoma ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - veterinary ; maintenance-free chemotherapy ; Male ; Medical Records ; prednisolone ; Prednisone - pharmacology ; Prognosis ; Schools, Veterinary ; survival ; Survival Analysis ; Treatment Outcome ; United States ; Vinca Alkaloids - pharmacology ; Vincristine - pharmacology</subject><ispartof>Veterinary & comparative oncology, 2016-08, Vol.14 (S1), p.136-146</ispartof><rights>2015 John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6818-87747d3d4cf4801425adcedfa40f6ee274d15768b753b41fe547ebc61270a4ee3</citedby><cites>FETCH-LOGICAL-c6818-87747d3d4cf4801425adcedfa40f6ee274d15768b753b41fe547ebc61270a4ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fvco.12158$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fvco.12158$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26109275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Collette, S. A.</creatorcontrib><creatorcontrib>Allstadt, S. D.</creatorcontrib><creatorcontrib>Chon, E. M.</creatorcontrib><creatorcontrib>Vernau, W.</creatorcontrib><creatorcontrib>Smith, A. N.</creatorcontrib><creatorcontrib>Garrett, L. D.</creatorcontrib><creatorcontrib>Choy, K.</creatorcontrib><creatorcontrib>Rebhun, R. B.</creatorcontrib><creatorcontrib>Rodriguez Jr, C. O.</creatorcontrib><creatorcontrib>Skorupski, K. A.</creatorcontrib><title>Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012)</title><title>Veterinary & comparative oncology</title><addtitle>Vet Comp Oncol</addtitle><description>CHOP‐based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance‐free CHOP‐based protocols have been published and readily used in dogs, there is limited literature regarding similar maintenance‐free protocols in cats. The purpose of this study was to describe the outcome of cats with intermediate‐ to high‐grade lymphoma that were prescribed a modified 25‐week University of Wisconsin–Madison (UW‐25) chemotherapy protocol. A secondary objective was examination of potential prognostic factors. One hundred and nineteen cats from five institutions treated with a UW‐25‐based protocol were included. The Kaplan–Meier median progression‐free interval (PFI) and survival time (MST) were 56 and 97 (range 2–2019) days, respectively. Cats assessed as having a complete response (CR) to therapy had significantly longer PFI and MST than those with partial or no response (PFI 205 versus 54 versus 21 days, respectively, P < 0.0001 and MST 318 versus 85 versus 27 days, respectively, P < 0.0001).</description><subject>alkaloids</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents, Alkylating - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>cat</subject><subject>Cat Diseases - drug therapy</subject><subject>Cats</subject><subject>CHOP</subject><subject>cyclophosphamide</subject><subject>Cyclophosphamide - pharmacology</subject><subject>dogs</subject><subject>doxorubicin</subject><subject>Doxorubicin - pharmacology</subject><subject>drug therapy</subject><subject>feline</subject><subject>Female</subject><subject>Kaplan-Meier Estimate</subject><subject>lymphoma</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - veterinary</subject><subject>maintenance-free chemotherapy</subject><subject>Male</subject><subject>Medical Records</subject><subject>prednisolone</subject><subject>Prednisone - pharmacology</subject><subject>Prognosis</subject><subject>Schools, Veterinary</subject><subject>survival</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>Vinca Alkaloids - pharmacology</subject><subject>Vincristine - pharmacology</subject><issn>1476-5810</issn><issn>1476-5829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1uEzEURkcIREthwQsgL9vFtLbHf2GBVEXQIgW6KbRiYzn2nYxhZhxsJyWPwFvwLDwZLmkjWCDhjS353KP76auq5wQfk3JO1jYcE0q4elDtEyZFzRWdPNy9Cd6rnqT0GWNKWUMfV3tUEDyhku9X3y8jmDzAmFFoUQu9HwH5MUMcwHmToUY5_PzR-UVXL6JxgPrNsOzCYNCNzx0yaAjOtx4cWo1-DTH5vLlVXflkw5j8WL8zzqcwomUMOdjQv0SETJA1CRI6pBizmmJCj55Wj1rTJ3h2dx9UH968vpye17OLs7fT01lthSKqVlIy6RrHbMsUJoxy4yy41jDcCgAqmSNcCjWXvJkz0gJnEuZWECqxYQDNQfVq612u5iWjLdGj6fUy-sHEjQ7G679_Rt_pRVhrXrZklBTB4Z0ghq8rSFkPJSv0vRkhrJImiomGNA3G_4ESrIRkShT0aIvaGFKK0O42IljftqxLy_p3y4V98WeEHXlfawFOtsCN72Hzb5P-OL24V9bbCZ8yfNtNmPhFC9lIrq_en-nz69mn6xmfadH8AgAewdo</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Collette, S. A.</creator><creator>Allstadt, S. D.</creator><creator>Chon, E. M.</creator><creator>Vernau, W.</creator><creator>Smith, A. N.</creator><creator>Garrett, L. D.</creator><creator>Choy, K.</creator><creator>Rebhun, R. B.</creator><creator>Rodriguez Jr, C. O.</creator><creator>Skorupski, K. A.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>201608</creationdate><title>Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012)</title><author>Collette, S. A. ; Allstadt, S. D. ; Chon, E. M. ; Vernau, W. ; Smith, A. N. ; Garrett, L. D. ; Choy, K. ; Rebhun, R. B. ; Rodriguez Jr, C. O. ; Skorupski, K. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6818-87747d3d4cf4801425adcedfa40f6ee274d15768b753b41fe547ebc61270a4ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>alkaloids</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents, Alkylating - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>cat</topic><topic>Cat Diseases - drug therapy</topic><topic>Cats</topic><topic>CHOP</topic><topic>cyclophosphamide</topic><topic>Cyclophosphamide - pharmacology</topic><topic>dogs</topic><topic>doxorubicin</topic><topic>Doxorubicin - pharmacology</topic><topic>drug therapy</topic><topic>feline</topic><topic>Female</topic><topic>Kaplan-Meier Estimate</topic><topic>lymphoma</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - veterinary</topic><topic>maintenance-free chemotherapy</topic><topic>Male</topic><topic>Medical Records</topic><topic>prednisolone</topic><topic>Prednisone - pharmacology</topic><topic>Prognosis</topic><topic>Schools, Veterinary</topic><topic>survival</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>Vinca Alkaloids - pharmacology</topic><topic>Vincristine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Collette, S. A.</creatorcontrib><creatorcontrib>Allstadt, S. D.</creatorcontrib><creatorcontrib>Chon, E. M.</creatorcontrib><creatorcontrib>Vernau, W.</creatorcontrib><creatorcontrib>Smith, A. N.</creatorcontrib><creatorcontrib>Garrett, L. D.</creatorcontrib><creatorcontrib>Choy, K.</creatorcontrib><creatorcontrib>Rebhun, R. B.</creatorcontrib><creatorcontrib>Rodriguez Jr, C. O.</creatorcontrib><creatorcontrib>Skorupski, K. A.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary & comparative oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Collette, S. A.</au><au>Allstadt, S. D.</au><au>Chon, E. M.</au><au>Vernau, W.</au><au>Smith, A. N.</au><au>Garrett, L. D.</au><au>Choy, K.</au><au>Rebhun, R. B.</au><au>Rodriguez Jr, C. O.</au><au>Skorupski, K. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012)</atitle><jtitle>Veterinary & comparative oncology</jtitle><addtitle>Vet Comp Oncol</addtitle><date>2016-08</date><risdate>2016</risdate><volume>14</volume><issue>S1</issue><spage>136</spage><epage>146</epage><pages>136-146</pages><issn>1476-5810</issn><eissn>1476-5829</eissn><abstract>CHOP‐based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance‐free CHOP‐based protocols have been published and readily used in dogs, there is limited literature regarding similar maintenance‐free protocols in cats. The purpose of this study was to describe the outcome of cats with intermediate‐ to high‐grade lymphoma that were prescribed a modified 25‐week University of Wisconsin–Madison (UW‐25) chemotherapy protocol. A secondary objective was examination of potential prognostic factors. One hundred and nineteen cats from five institutions treated with a UW‐25‐based protocol were included. The Kaplan–Meier median progression‐free interval (PFI) and survival time (MST) were 56 and 97 (range 2–2019) days, respectively. Cats assessed as having a complete response (CR) to therapy had significantly longer PFI and MST than those with partial or no response (PFI 205 versus 54 versus 21 days, respectively, P < 0.0001 and MST 318 versus 85 versus 27 days, respectively, P < 0.0001).</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>26109275</pmid><doi>10.1111/vco.12158</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-5810 |
| ispartof | Veterinary & comparative oncology, 2016-08, Vol.14 (S1), p.136-146 |
| issn | 1476-5810 1476-5829 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5012421 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | alkaloids Animals Antibiotics, Antineoplastic - pharmacology Antineoplastic Agents - pharmacology Antineoplastic Agents, Alkylating - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology cat Cat Diseases - drug therapy Cats CHOP cyclophosphamide Cyclophosphamide - pharmacology dogs doxorubicin Doxorubicin - pharmacology drug therapy feline Female Kaplan-Meier Estimate lymphoma Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - veterinary maintenance-free chemotherapy Male Medical Records prednisolone Prednisone - pharmacology Prognosis Schools, Veterinary survival Survival Analysis Treatment Outcome United States Vinca Alkaloids - pharmacology Vincristine - pharmacology |
| title | Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T18%3A40%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20feline%20intermediate-%20to%C2%A0high-grade%20lymphoma%20with%20a%20modified%20university%20of%20Wisconsin-Madison%20protocol:%20119%20cases%20(2004-2012)&rft.jtitle=Veterinary%20&%20comparative%20oncology&rft.au=Collette,%20S.%20A.&rft.date=2016-08&rft.volume=14&rft.issue=S1&rft.spage=136&rft.epage=146&rft.pages=136-146&rft.issn=1476-5810&rft.eissn=1476-5829&rft_id=info:doi/10.1111/vco.12158&rft_dat=%3Cproquest_pubme%3E1846313300%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1810867486&rft_id=info:pmid/26109275&rfr_iscdi=true |